Overview of the management of Type 2 diabetes

Diabetes/Metabolism Reviews

Volumn 14, Issue SUPPL. 1, 1998, Pages

  Standl, Eberhard ^a  

^a Klinikum Schwabing   (Germany)

Author keywords

HbA(1c); NIDDM; Type 2 diabetes

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; HEMOGLOBIN A1C; INSULIN; SULFONYLUREA; TROGLITAZONE;

CONFERENCE PAPER; DIABETIC ANGIOPATHY; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; VASCULAR DISEASE;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; MIDDLE AGED; RISK FACTORS; SURVIVAL RATE;

EID: 0031795736     PISSN: 07424221     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0895(199809)14:1+3.0.CO;2-D     Document Type: Conference Paper

References (13)

1. Thoelke H and Meusel K: Zur Überlebensdauer von Typ-II-Diabetikern. Ergebnisse einer 20 jährigen Follow-up-Studie in Berlin Ost. Diskussionsbeiträge zur Gesundheitsforschung ( # 19), Senatsverwaltung für Gesundheit Berlin, 1994, pp. 1-33.
2. Panzram G, et al.: Mortality and survival in Type 2 (non-insulin dependent) diabetes mellitus. Diabetologia 30: 123-131, 1987.
3. Klein R: Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 18: 258-268, 1995.
4. Kuusisto J, Mykkänen L, Pyörälä K, and Laakso M: NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 43: 960-967, 1994.
5. Standl E, Balletshofer B, Dahl B, Weichenhain B, Stiegler H, Hormann A, and Holle R: Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia 39: 1540-1545, 1996.
6. Bayerische Landesärztekammer und Fachkommission: Diabetes in Bayern: Rationale und rationelle Diagnostik und Therapie des Diabetes mellitus. Verlag der Bayer Laundesärztekammer, 1995.
7. Taranov L, Rossing P, Nielsen FS, Hansen BV, Dyerberg HJ, and Parving HH: Increased plasma apolipoprotein (a) levels in IDDM patients with diabetic nephropathy. Diabetes Care 19: 1392-1387, 1996.
8. Standl E: Hyperinsulinemia and atherosclerosis. In The Metabolic Syndrome, Hanefeld M, and Leonhardt WG, Eds. Fischer, Leipzig, 1997, pp 140-147.
9. Janka et al.: The metabolic syndrome as a potent risk factor for premature death in NIDDM. Diabetes und Stoffwechsel 1: 2-7, 1992.
10. Turner R, Cull C, and Holman R: United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control of complications in non insulin-dependent diabetes mellitus. Ann Intern Med 124 (1 pt 2): 136-145, 1996.
11. Standl E: New drugs for diabetes. In The Diabetes Annual/10, Marshall SM, Home PD, and Rizza RA, Eds. Elsevier, Amsterdam, 1996, pp. 225-249.
12. Harris MI, Klein R, Welborg TA, and Knuiman MW: Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 15: 815-819, 1992.
13. Standl E, and Stiegler H: Microalbuminuria in a random cohort of recently diagnosed Type 2 (non-insulin-dependent) diabetic patients living in the greater Munich area. Diabetologia 36: 1017-1020, 1993.